Status: Not yet recruiting
A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.
This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary pharmacodynamic characteristics of GR2301 injection in healthy adult subjects in China.The GR2301 injection dosage will be gradually increased. All healthy subjects will receive a single subcutaneous injection. Following administration, subjects will be followed for at least 16 weeks ± 7 days.
Participants needed: 36
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.Updated: Sep 24, 2025Locations: 1
Eligibility criteria
BMI 19.0-28.0 kg/m², with male subjects weighing ≥50.0 kg and female subjects we... [+1]
A history of past or current conditions involving the nervous system, cardiovasc... [+2]